Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-10T12:25:51.913Z Has data issue: false hasContentIssue false
  • English
  • Français

Pregabalin-induced sexual disinhibition

Published online by Cambridge University Press:  08 March 2017

R. Murphy ,
D. McGuinness  and
B. Hallahan
R. Murphy
Affiliation:
School of Medicine, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland University Hospital Galway, Galway Roscommon Mental Health Services, Galway, Ireland
D. McGuinness
Affiliation:
University Hospital Galway, Galway Roscommon Mental Health Services, Galway, Ireland
B. Hallahan*
Affiliation:
School of Medicine, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland University Hospital Galway, Galway Roscommon Mental Health Services, Galway, Ireland
*
*Address for correspondence: Dr B. Hallahan, Senior Lecturer in Psychiatry, School of Medicine, Clinical Science Institute, National University of Ireland Galway, Galway, Ireland. (Email: brian.hallahan@nuigalway.ie)
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction

Sexual side effects have rarely been reported secondary to treatment with Pregabalin, a structural analogue of the inhibitory neurotransmitter gamma amino butyric acid (GABA).

Method

We present the case of AB, a 27-year-old single man with a diagnosis of recurrent depressive disorder who was prescribed pregabalin to alleviate the significant anxiety symptoms he was experiencing.

Results

A significant amelioration in anxiety symptoms was attained; however, he developed the adverse effects of acute sexual disinhibition and increased libido. These adverse effects were temporally related to treatment with pregabalin and reduced with dose reduction of this agent.

Conclusions

To date, limited published data are available relating such a reaction to pregabalin. A greater clinical recognition of this association between pregabalin and sexual disinhibition, would allow clinicians to intervene at an earlier stage of this adverse effect and potentially as in this case, management may only require dose reduction rather than treatment discontinuation.

Keywords

Pregabalinrecurrent depressive disordersexual disinhibition
Type
Case Report
Information
Irish Journal of Psychological Medicine , Volume 37 , Issue 1 , March 2020 , pp. 55 - 58
Copyright
© College of Psychiatrists of Ireland 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldwin, DS, Ajel, K (2007). Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment 3, 185–191.CrossRefGoogle ScholarPubMed
Bucur, M, Jeczmien, M (2011). Pregabalin and libido case reports. The Open Neuropsychopharmacology Journal 4, 8–9.CrossRefGoogle Scholar
Finnerup, NB, Jensen, TS (2007). Clinical use of pregabalin in the management of central neuropathic pain. Neuropsychiatric Disease and Treatment 3, 885–891.CrossRefGoogle ScholarPubMed
Frampton, JE (2014). Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 28, 835–854.CrossRefGoogle ScholarPubMed
Greil, W, Horvath, A, Sassim, N, Erazo, N, Grohmann, R (2001). Disinhibition of libido: an adverse effect of SSRI? Journal of Affective Disorders 62, 225–228.CrossRefGoogle ScholarPubMed
Hill, DR, Suman-Chauhan, N, Woodruff, GN (1993). Localization of [3H] gabapentin to a novel site in rat brain: autoradiographic studies. European Journal of Pharmacology 244, 303–309.CrossRefGoogle Scholar
Jerome, L (2007). Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. Pain Research and Management 12, 212–214.CrossRefGoogle Scholar
Lam, MHB, Fong, SYY, Wing, Y-K (2007). Sexual disinhibition in schizophrenia possibly induced by risperidone and quetiapine. Psychiatry and Clinical Neurosciences 61, 333.CrossRefGoogle ScholarPubMed
Leonhart, M (2005). Schedules of controlled substances: placement of pregabalin into schedule V. Federal Register 70, 43633–43635.Google Scholar
Li, Z, Taylor, CP, Weber, M, Piechan, J, Prior, F, Bian, F, Cui, M, Hoffman, D, Donevan, S (2011). Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel subunits. European Journal of Pharmacology 667, 80–90.CrossRefGoogle ScholarPubMed
Osman, M, Casey, P (2014). Pregabalin abuse for enhancing sexual performance: case discussion and literature review. Irish Journal of Psychological Medicine 31, 281–286.CrossRefGoogle ScholarPubMed
Oulis, P, Kouzoupis, AV, Koulouris, G, Masdrakis, VG, Kontoangelos, K, Matsoukas, T, Papadimitriou, GN (2008). Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder. Journal of Clinical Psychopharmacology 28, 362–363.CrossRefGoogle ScholarPubMed
Pacchiarotti, I, Manfredi, G, Kotzalidis, GD, Giradi, P, Tartelli, R (1993). Quetiapine-induced mania. Australian & New Zealand Journal of Psychiatry 37, 626.Google Scholar
Paton, C (2002). Drug information quarterly. Benzodiazepines and disinhibition: a review. Psychiatric Bulletin 26, 460–462.CrossRefGoogle Scholar
Schwan, S, Sundstrom, A, Stjernberg, E, Hallberg, E, Hallberg, P (2010). A signal for an abuse liability for pregabalin – results from the Swedish spontaneous adverse drug reaction reporting system. European Journal of Clinical Pharmacology 66, 947–953.CrossRefGoogle ScholarPubMed
Vranken, JH, Dijkgraaf, MGW, Kruis, MR, van der Vegt, MH, Hollmann, MW, Heesen, M (2008). Pregabalin in patients with central neuropathic pain: a randomized double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 136, 150–157.CrossRefGoogle ScholarPubMed
Yargic, I, Ozdemiroglu, FA (2011). Pregabalin abuse: a case report. Bulletin of Clinical Psychopharmacology 21, 64–66.CrossRefGoogle Scholar